Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)
Tyra Biosciences (Nasdaq: TYRA) announced three abstracts for presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) in Barcelona, Spain, from October 23-25, 2024. The presentations include:
1. A late-breaking oral presentation on the preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301).
2. A poster on the preliminary pharmacokinetic and pharmacodynamic analysis of TYRA-300 from the SURF301 study.
3. A poster on the multicenter, open-label Phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 gene alterations (SURF301).
The abstracts are embargoed until 00.01 hrs CEST on Friday, October 25, 2024.
Tyra Biosciences (Nasdaq: TYRA) ha annunciato tre abstract per la presentazione al 36° Simposio EORTC-NCI-AACR sui Target Molecolari e le Terapie Antitumorali (ENA 2024) a Barcellona, Spagna, dal 23 al 25 ottobre 2024. Le presentazioni includono:
1. Una presentazione orale a rilevanza tardiva sulla sicurezza preliminare e sull'attività antitumorale di TYRA-300, un inibitore altamente selettivo di FGFR3, in partecipanti con tumori solidi avanzati con mutazioni/fusioni attivanti FGFR3 (SURF301).
2. Un poster sull'analisi preliminare della farmacocinetica e della farmacodinamica di TYRA-300 dallo studio SURF301.
3. Un poster sullo studio multicentrico, in aperto Fase 1/2 di TYRA-300 in carcinoma uroteliale avanzato e altri tumori solidi con alterazioni geniche FGFR3 attivanti (SURF301).
Gli abstract sono soggetti a embargo fino alle 00:01 ore CEST di venerdì 25 ottobre 2024.
Tyra Biosciences (Nasdaq: TYRA) anunció tres resúmenes para su presentación en el 36º Simposio EORTC-NCI-AACR sobre Objetivos Moleculares y Terapias contra el Cáncer (ENA 2024) en Barcelona, España, del 23 al 25 de octubre de 2024. Las presentaciones incluyen:
1. Una presentación oral de última hora sobre la seguridad preliminar y la actividad antitumoral de TYRA-300, un inhibidor altamente selectivo de FGFR3, en participantes con tumores sólidos avanzados con mutaciones/fusiones activadoras de FGFR3 (SURF301).
2. Un póster sobre el análisis preliminar farmacocinético y farmacodinámico de TYRA-300 del estudio SURF301.
3. Un póster sobre el estudio multicéntrico, abierto, de Fase 1/2 de TYRA-300 en carcinoma urotelial avanzado y otros tumores sólidos con alteraciones genéticas activadoras de FGFR3 (SURF301).
Los resúmenes están sujetos a embargo hasta las 00:01 horas CEST del viernes 25 de octubre de 2024.
Tyra Biosciences (Nasdaq: TYRA)는 2024년 10월 23일부터 25일까지 스페인 바르셀로나에서 열리는 제36회 EORTC-NCI-AACR 분자 타겟 및 암 치료 심포지엄(ENA 2024)에서 발표할 세 가지 초록을 발표했습니다. 발표 내용은 다음과 같습니다:
1. 최신 발표로서 TYRA-300의 탐색적 안전성과 항종양 활성에 대한 내용이 포함되며, 이는 FGFR3 변이/융합을 가지는 진행성 고형 종양 환자에서 FGFR3의 높은 선택성을 가진 억제제입니다 (SURF301).
2. SURF301 연구에서 TYRA-300의 초기 약동학 및 약력학 분석에 대한 포스터입니다.
3. FGFR3 유전자 변이로 인해 진행성 요도암 및 기타 고형 종양에서 TYRA-300의 다기관 공개 라벨 1/2상 연구에 대한 포스터입니다 (SURF301).
초록은 2024년 10월 25일 금요일 CEST 00:01까지 보류됩니다.
Tyra Biosciences (Nasdaq: TYRA) a annoncé trois résumés pour présentation lors du 36e Symposium EORTC-NCI-AACR sur les cibles moléculaires et les thérapies contre le cancer (ENA 2024) qui se tiendra à Barcelone, Espagne, du 23 au 25 octobre 2024. Les présentations comprennent :
1. Une présentation orale tardive sur la sécurité préliminaire et l'activité antitumorale de TYRA-300, un inhibiteur hautement sélectif de FGFR3, chez des participants atteints de tumeurs solides avancées présentant des mutations/fusions FGFR3 activantes (SURF301).
2. Un poster sur l'analyse préliminaire pharmacocinétique et pharmacodynamique de TYRA-300 à partir de l'étude SURF301.
3. Un poster sur l'étude multicentrique, ouverte de Phase 1/2 de TYRA-300 dans le carcinome urotélial avancé et d'autres tumeurs solides avec des altérations génétiques FGFR3 activantes (SURF301).
Les résumés sont sous embargo jusqu'à 00h01 CEST le vendredi 25 octobre 2024.
Tyra Biosciences (Nasdaq: TYRA) gab bekannt, dass drei Abstracts auf dem 36. EORTC-NCI-AACR-Symposium zu Molekularen Zielen und Krebsbehandlungen (ENA 2024) in Barcelona, Spanien, vom 23. bis 25. Oktober 2024 präsentiert werden. Die Präsentationen umfassen:
1. Eine spontane mündliche Präsentation zur vorläufigen Sicherheit und antitumoralen Aktivität von TYRA-300, einem hochselektiven FGFR3-Inhibitor, bei Teilnehmern mit fortgeschrittenen soliden Tumoren mit aktivierenden FGFR3-Mutationen/Fusionen (SURF301).
2. Ein Poster zur vorläufigen pharmazeutischen und pharmakologischen Analyse von TYRA-300 aus der SURF301-Studie.
3. Ein Poster zur multizentrischen, offenen Phase 1/2-Studie von TYRA-300 bei fortgeschrittenem Urothelkarzinom und anderen soliden Tumoren mit aktivierenden FGFR3-Genveränderungen (SURF301).
Die Abstracts sind bis 00:01 Uhr CEST am Freitag, den 25. Oktober 2024, unter embargo.
- Selection of three abstracts for presentation at a major cancer therapeutics symposium
- Late-breaking oral presentation slot for TYRA-300 preliminary safety and anti-tumor activity data
- Ongoing clinical trials (SURF301) for TYRA-300 in advanced solid tumors with FGFR3 mutations/fusions
- None.
-TYRA will also present two posters on PK/PD of TYRA-300 and a Trials-in-Progress from SURF301 -
Details of the presentations are below:
Title: "Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)"
Session: Late Breaking Abstracts and Proffered Papers: Novel discoveries in drug development
Date: Friday, October 25, 2024
Time: 15:36 - 15:48 hrs CEST
Abstract #: LBA500
Title: "TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations"
Abstract #: 72
Poster #: PB060
Title: "A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF301)"
Abstract #: 35
Poster #: PB023
The abstracts related to the presentations are under embargo until 00.01 hrs CEST on Friday, October 25, 2024.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in
For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-announces-late-breaking-oral-presentation-on-preliminary-safety-and-anti-tumor-activity-of-tyra-300-from-surf301-at-the-36th-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics-ena-2024-302273982.html
SOURCE Tyra Biosciences
FAQ
What is TYRA-300 and what is it being studied for?
When and where will Tyra Biosciences (TYRA) present its TYRA-300 data at ENA 2024?
How many abstracts will Tyra Biosciences (TYRA) present at ENA 2024?
What is the SURF301 study mentioned in Tyra Biosciences' (TYRA) presentations?
